Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib vs placebo in HCC after sorafenib
CTR20131723Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Apr 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20131723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131723.